medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2005, Número 04

<< Anterior Siguiente >>

Ginecol Obstet Mex 2005; 73 (04)


Posición Latinoamericana en Relación con el Estado Actual de la Terapia Hormonal

Figueroa CP, Siseles N, Albernaz MA, Chada BE, Cristina BI, Bossemeyer R, Eduardo FC, Maia FH, de Melo NR, Rodrigues DG, Monterrosa CA, González CO, Carranza LS, Espinosa LF, Hernández BA, Murillo UA, Santos GJ, Molina VR

Idioma: Español
Referencias bibliográficas: 26
Paginas: 205-211
Archivo PDF: 60.85 Kb.


FRAGMENTO

Para discutir y establecer una posición conjunta en Latinoamérica con respecto al estado actual de la terapia hormonal (TH) con estrógenos solos y estrógenos más progestina durante la transición a la menopausia y el climaterio, se reunió en la ciudad de Bahía, Salvador, Brasil, del 1 al 3 de octubre del 2004, un grupo de profesionales interesados en la atención de la salud de la mujer que se constituyeron en grupo editorial especializado en terapia hormonal.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kronenberg F. Hot flashes. In: Lobo RA, editor. Treatment of the Post Menopausal Woman. Philadelphia: Lippincott William & Wilkins, 1999;pp:157-77.

  2. Randoph JF, Sowers M, Gold EB, et al. Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size and menopausal status. J Clin Endocrinol Metab 2003;88:1516-22.

  3. Kronenberg F, Barnard RM. Modulation of menopausal hot flashes by ambient temperature. J Therm Biol 1992;17:43-49.

  4. Rossouw JE, Anderson GL, Prentice RL, et al. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-33.

  5. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34.

  6. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women’s Health Initiative Randomized Trial. JAMA 2003;289:3243-53.

  7. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419-27.

  8. Fernandes CE, Soares-Pereira A, Bonassi-Machado R, et al. Consenso da SOBRAC- Associaçao Brasileira de Climatério. Terapeutica Hormonal na pero e na pós-menopausa. Cap. 7. Sao Paulo: Medcomm, 2004.

  9. Basavilvazo MA, Bravo-Rodriguez LM, Carranza-Lira S, et al. Primer Consenso Nacional Multidisciplinario sobre Terapia de Reemplazo Hormonal. Rev del Clim 2004;7(40):156-79.

  10. Campodónico I, Siseles N, Gutiérrez P, Belardo A, et al. Consenso Latinoamericano sobre Terapia Hormonal Postmenopáusica (Memoria Mecanograma). Salta, Argentina 14-15 de agosto del 2003.

  11. Research Group. Heart Estrogen/progestin Replacement Study (HERS). JAMA 1998;280:605-13.

  12. Research Group. Heart Estrogen/progestin Replacement Study (HERS II). JAMA 2002;288:49-57.

  13. Herrington DM, et al. Estrogen Replacement and Atherosclerosis Study (ERAS). N Engl J Med 2000;343:522-9.

  14. Grodstein F, Stamfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61.

  15. Guidelines for the hormone treatment of women in the menopausal transition and beyond. Position Statement by the Executive Committee of the International Menopause Society. Climacteric 2004;7:8-11.

  16. The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.

  17. Shapiro S. Effects of HRT on the risks of breast cancer and cardiovascular disease; the validity of the epidemiological evidence. In: Schneider HPG, Naftolin F, editors. Climacteric Medicine- Where do we go? Proceedings of the 4th Workshop of the International Menopause Society. London: Parthenon Publishing, 2004;pp:166-74.

  18. Aksel S, Schomberg DW, Tyrey L, Hammond CB. Vasomotor symptoms, serum estrogen and gonadotropin levels in surgical menopause. Am J Obstet Gynecol 1976;126:165-9.

  19. Hutton JD, Jacobs HS, Murray MAF, James VHT. Relation between plasma oestrone and oestradiol and climacteric symptoms. Lancet 1978;1:671-81.

  20. North American Menopause Society. Estrogens and Progestogen use in peri and postmenopausal women. September 2003. Position Statement of the North American Menopause Society. Menopause 2003;10:497-506.

  21. North American Menopause Society. Treatment of menopause associated vasomotor symptoms: position statement of the North American Menopause Society. Menopause 2004;11:11-33.

  22. MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes (Cochrane Review). Cochrane Database Syst Rev 2001;1:CD002978.

  23. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet 2000;356:2059-63.

  24. Stearns V, Issacs C, Rowland J, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000;11:17-22.

  25. Loprinzi L, Barton DL, Sloan JA, et al. Pilot evaluation of gabapentin for treatment hot flashes. Mayo Clin Proc 2002;77:1159-63.

  26. Nesheim BI, Saetre T. Reduction of menopausal hot flashes by methyldopa: a double blind crossover trial. Eur J Clin Pharmacol 1981;20:413-6.




2020     |     www.medigraphic.com